Metastatic Prostate Cancer: Optimization of Systemic Treatment

Wednesday, 3 July 2024 | Urogenital

Clinical trials investigating various drugs in patients with metastatic hormone-sensitive or castration-resistant prostate cancer have revealed significant benefits. While research is ongoing to shed light on issues such as sequencing, treatment de-escalation and biomarkers, translating the accepted evidence into everyday clinical practice still represents a challenge.

Deborah Mukherji

Clemenceau Medical Center, Dubai

Explore More

OncoNews

OncoNews

Lung Icon

Lung Cancer

Uterus Icon

Women's Cancers

Bladder Icon

Urogenital

GI Icon

Gastro-intestinal

Hematology Icon

Hematology

Other Solid Tumor Icon

Other Tumors

Related Posts

Leading Opinions

This article was produced in cooperation with our partners at Leading Opinions Hämatologie & Onkologie, published by Universimed. The original article in its original language can be found via universimed.com and med-diplom.ch.

To continue, please login or sign up first